CryoPort (CYRX) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
CryoPort (CYRX) has outperformed Savara (SVRA) over the past year, gaining 66.4% versus a gain of 23.3%. Over five years, SVRA leads with a +267.8% price change compared with -78.3% for CYRX. Savara is the larger company by market cap ($914.3 million vs $852.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYRX | SVRA |
|---|---|---|
| Share price | $16.84 | $4.45 |
| Market cap | $852.93M | $914.30M |
| 1-day change | -1.35% | -6.12% |
| YTD return | +75.42% | -26.20% |
| 1-year return | +66.40% | +23.27% |
| 5-year return | -78.30% | +267.77% |
| EPS (TTM) | $-0.81 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $176.18M | — |
| Revenue growth (YoY) | +12.38% | — |
| Net income (latest FY) | $78.30M | $-118.84M |
| Gross margin | 47.14% | — |
| Operating margin | -20.89% | — |
| Net margin | 44.44% | — |
| 52-week high | $18.36 | $7.01 |
| 52-week low | $7.61 | $3.60 |
| Distance from 52-week high | -8.28% | -36.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +16.81% | +148.54% |
| Average volume | 629.77K | 1.90M |
| Shares outstanding | 50.65M | 205.46M |
| Employees | 684 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYRX has outperformed SVRA by 43.1 percentage points over the past year.
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
CYRX vs SVRA FAQ
Which is bigger, CryoPort or Savara?
Savara (SVRA) is larger, with a market capitalization of $914.30M compared with $852.93M for CryoPort (CYRX).
Which stock has performed better over the past year, CYRX or SVRA?
CYRX returned +66.40% over the past 12 months, compared with +23.27% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are CryoPort and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.